Cocrystal’s COVID-19 antiviral CDI-45205 shown to be active against SARS-CoV-2 and prominent SARS-CoV-2 variants
On Jun. 14, 2021, Cocrystal Pharma announced the selection of CDI-45205 as the lead compound for further development…
RECOVERY trial found aspirin does not improve survival for patients hospitalised with COVID-19
On Jun. 8, 2021, the University of Oxford announced that the RECOVERY trial found aspirin does not improve…
Patient enrollment reached 90 percent in Innovation Pharma’s phase 2 clinical trial of brilacidin for COVID-19
On May 27, 2021, Innovation Pharma announced that patient enrollment in the Company’s 120-patient, Phase 2 clinical trial…
Pfizer and BioNTech announced supplying EU with up to 1.8 billion additional doses of COMIRNATY
On May 20, 2021, Pfizer and BioNTech announced a new agreement with the European Commission (EC) to supply…
Pfizer and BioNTech submitted request to expand conditional marketing authorization of COMIRNATY in EU to adolescents
On Apr. 29, 2021, Pfizer and BioNTech announced they had submitted a variation to the Conditional Marketing Authorization…
Biotechnology | Cartoons - Original | CDC | COVID-19 | Diagnostics | Life Science History | Medicine | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | USDA | Vaccine | WHO
COVID-19 science and reason
COVID-19 and it’s naysayers are attacking Science and Reason. The defenders must suffer the slings and arrows from…
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY
On Apr. 19, 2021, Pfizer and BioNTech announced supplying an additional 100 million doses of COMIRNATY, the companies…
Merck discontinued development of MK-7110 for COVID-19
On Apr. 15, 2021, Merck announced the discontinuation of development of MK-7110 (formerly known as CD24Fc) for the…
Johnson & Johnson announced agreement with African Vaccine Acquisition Trust for COVID-19 vaccine candidate
On Mar. 29, 2021, Janssen Pharmaceutica announced that it had entered into an agreement with the African Vaccine…
Pfizer initiated phase 1 study of movel oral antiviral therapeutic agent against SARS-CoV-2
On Mar. 23, 2021, Pfizer announced that it was progressing to multiple ascending doses after completing the dosing…
COVID-19 | Pharmaceutical | Vaccine | WHO
WHO COVID-19 subcommittee announced safety signals related to AstraZeneca COVID-19 vaccine
On Mar. 17, 2021, the WHO reported that the AstraZeneca COVID-19 vaccine (including Covishield) continued to have a…
Recruitment and enrollment began for Innovation Pharma’s phase 2 clinical trial of Brilacidin for COVID-19
On Mar. 5, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Company’s international Phase 2…
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics | Vaccine
Pfizer and BioNTech submited COVID-19 vaccine stability data at standard freezer temperature to the FDA
On Feb. 19, 2021, BioNTech announced the submission of new data to the FDA demonstrating the stability of…
Corvus Pharmaceuticals initiated phase 3 clinical trial of CPI-006 for patients with COVID-19
On Feb. 4, 2021, Corvus Pharmaceuticals announced that it had initiated a Phase 3 clinical trial of CPI-006…
Regeneron reported positive data with REGEN-COV antibody cocktail as passive vaccine to prevent COVID-19
On Jan. 26, 2021, Regeneron announced positive initial results from an ongoing Phase 3 clinical trial evaluating REGEN-COV…
Low-dose aspirin may improve pregnancy chances for women with one or two prior miscarriages
On Jan. 25, 2021, the National Institutes of Health (NIH) announced that in large clinical trial conducted worldwide,…
RedHill’s phase 2/3 COVID-19 study of opaganib passed second DSMB with unanimous recommendation
On Dec. 22, 2020, RedHill Biopharma announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva, ABC294640)1…
Cocrystal Pharma selected lead compound for further development against Coronaviruses
On Dec. 22, 2020, Cocrystal Pharma announced the selection of CDI-45205 as the lead compound for further development…
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY
On Dec. 19, 2020, Pfizer and BioNTech announced they supplying an additional 100 million doses of COMIRNATY the…
RedHill’s phase 2/3 COVID-19 candidate opaganib reduced ARDS-related blood clotting in preclinical model
On Dec. 15, 2020, a months long study to determine the number of Houstonians carrying COVID-19 antibodies revealed…
Aurinia and Lonza announced exclusive agreement for dedicated Voclosporin manufacturing capacity
On Dec. 15, 2020, Aurinia Pharmaceuticals announced the funding and initiation of an open-label exploratory trial evaluating the…
Bankruptcy judge approved federal settlement with Purdue Pharma
On Nov. 17, 2020, the proposed settlements between the federal government and OxyContin maker Purdue Pharma and its…
Seagen announced closing of $1.0 billion stock sale to Merck
On Oct. 28, 2020, Seagen announced the closing of a $1.0 billion equity investment by Merck in 5.0…
Purdue Pharma reached agreement with U.S. Department of Justice
On Oct. 21, 2020, Purdue Pharma announced that it had entered into an agreement with the U.S. Department…
Agriculture | Artificial Intelligence | Biotechnology | CMO | CRO | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
U.S. Department of Defense approved $87 million for newest bioindustrial manufacturing innovation institute
On Oct. 20, 2020, the U.S. Department of Defense announced an $87 million, seven-year award to the BioIndustrial…
Alberta Enterprise Corporation invested additional $5 million to benefit Alberta startups
On Oct. 19, 2020, Alberta Enterprise announced that it had invested an additional $5 million into its third…
RedHill Biopharma announced partnerships to expand manufacturing for COVID-19 therapeutic candidate opaganib
On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to…
RedHill Biopharma’s Opaganib COVID-19 study passed second independent committee review
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
Data from Corvus phase 1 study of CPI-006 continued to support its potential as treatment for COVID-19
On Oct. 5, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a…
New anti-infective drugs had a 14% speed advantage vs other drugs from 2000-2019
On Sept. 15, 2020, the Tufts Center for the Study of Drug Development reported that new anti-infective drugs…